CN104547534A - 一种具有缓解视疲劳功效的中草药保健口服液 - Google Patents
一种具有缓解视疲劳功效的中草药保健口服液 Download PDFInfo
- Publication number
- CN104547534A CN104547534A CN201510054127.6A CN201510054127A CN104547534A CN 104547534 A CN104547534 A CN 104547534A CN 201510054127 A CN201510054127 A CN 201510054127A CN 104547534 A CN104547534 A CN 104547534A
- Authority
- CN
- China
- Prior art keywords
- parts
- radix
- oral liquid
- chinese herbal
- herbal medicine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 69
- 241000411851 herbal medicine Species 0.000 title claims abstract description 40
- 230000036541 health Effects 0.000 title claims abstract description 33
- 208000003464 asthenopia Diseases 0.000 title claims abstract description 32
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 72
- 210000000582 semen Anatomy 0.000 claims abstract description 28
- 239000000341 volatile oil Substances 0.000 claims abstract description 26
- 238000000605 extraction Methods 0.000 claims abstract description 19
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 16
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 16
- 235000008434 ginseng Nutrition 0.000 claims abstract description 16
- 238000004821 distillation Methods 0.000 claims abstract description 7
- 238000005516 engineering process Methods 0.000 claims abstract description 5
- 239000000243 solution Substances 0.000 claims description 37
- 239000002994 raw material Substances 0.000 claims description 33
- 241000628997 Flos Species 0.000 claims description 26
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 26
- 241000208340 Araliaceae Species 0.000 claims description 15
- 238000001914 filtration Methods 0.000 claims description 15
- 238000002156 mixing Methods 0.000 claims description 15
- UAJTZZNRJCKXJN-UHFFFAOYSA-M sodium;2-dodecoxy-2-oxoethanesulfonate Chemical compound [Na+].CCCCCCCCCCCCOC(=O)CS([O-])(=O)=O UAJTZZNRJCKXJN-UHFFFAOYSA-M 0.000 claims description 13
- 238000000034 method Methods 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 11
- 239000007864 aqueous solution Substances 0.000 claims description 10
- 230000001804 emulsifying effect Effects 0.000 claims description 10
- 238000010438 heat treatment Methods 0.000 claims description 10
- 239000002244 precipitate Substances 0.000 claims description 10
- 239000000047 product Substances 0.000 claims description 10
- 239000011265 semifinished product Substances 0.000 claims description 10
- 238000003756 stirring Methods 0.000 claims description 10
- 230000008569 process Effects 0.000 claims description 7
- 108090000790 Enzymes Proteins 0.000 claims description 6
- 102000004190 Enzymes Human genes 0.000 claims description 6
- 229940088598 enzyme Drugs 0.000 claims description 6
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 claims description 5
- 108010059892 Cellulase Proteins 0.000 claims description 5
- 229920002472 Starch Polymers 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000010009 beating Methods 0.000 claims description 5
- 229940106157 cellulase Drugs 0.000 claims description 5
- 239000006184 cosolvent Substances 0.000 claims description 5
- 230000006837 decompression Effects 0.000 claims description 5
- 238000004945 emulsification Methods 0.000 claims description 5
- 239000000284 extract Substances 0.000 claims description 5
- 150000004676 glycans Chemical class 0.000 claims description 5
- 235000008216 herbs Nutrition 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 239000012535 impurity Substances 0.000 claims description 5
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 claims description 5
- 229920001282 polysaccharide Polymers 0.000 claims description 5
- 239000005017 polysaccharide Substances 0.000 claims description 5
- 229920000053 polysorbate 80 Polymers 0.000 claims description 5
- 239000004302 potassium sorbate Substances 0.000 claims description 5
- 229940069338 potassium sorbate Drugs 0.000 claims description 5
- 235000010241 potassium sorbate Nutrition 0.000 claims description 5
- 238000010298 pulverizing process Methods 0.000 claims description 5
- 238000004064 recycling Methods 0.000 claims description 5
- 235000019698 starch Nutrition 0.000 claims description 5
- 239000008107 starch Substances 0.000 claims description 5
- 238000002604 ultrasonography Methods 0.000 claims description 5
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- AYRXSINWFIIFAE-SCLMCMATSA-N Isomaltose Natural products OC[C@H]1O[C@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)[C@@H](O)[C@@H](O)[C@@H]1O AYRXSINWFIIFAE-SCLMCMATSA-N 0.000 claims description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 3
- DLRVVLDZNNYCBX-RTPHMHGBSA-N isomaltose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)C(O)O1 DLRVVLDZNNYCBX-RTPHMHGBSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 3
- 229960002675 xylitol Drugs 0.000 claims description 3
- 235000010447 xylitol Nutrition 0.000 claims description 3
- 239000000811 xylitol Substances 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 22
- 239000000463 material Substances 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 235000013399 edible fruits Nutrition 0.000 abstract description 2
- 240000000249 Morus alba Species 0.000 abstract 2
- 235000008708 Morus alba Nutrition 0.000 abstract 2
- 241000382455 Angelica sinensis Species 0.000 abstract 1
- 241000205585 Aquilegia canadensis Species 0.000 abstract 1
- 235000007516 Chrysanthemum Nutrition 0.000 abstract 1
- 244000189548 Chrysanthemum x morifolium Species 0.000 abstract 1
- 244000037364 Cinnamomum aromaticum Species 0.000 abstract 1
- 235000014489 Cinnamomum aromaticum Nutrition 0.000 abstract 1
- 241001289529 Fallopia multiflora Species 0.000 abstract 1
- 240000000691 Houttuynia cordata Species 0.000 abstract 1
- 235000013719 Houttuynia cordata Nutrition 0.000 abstract 1
- 241000830535 Ligustrum lucidum Species 0.000 abstract 1
- 244000241838 Lycium barbarum Species 0.000 abstract 1
- 235000015459 Lycium barbarum Nutrition 0.000 abstract 1
- 235000015468 Lycium chinense Nutrition 0.000 abstract 1
- 244000131316 Panax pseudoginseng Species 0.000 abstract 1
- 244000042430 Rhodiola rosea Species 0.000 abstract 1
- 235000003713 Rhodiola rosea Nutrition 0.000 abstract 1
- 244000272459 Silybum marianum Species 0.000 abstract 1
- 235000010841 Silybum marianum Nutrition 0.000 abstract 1
- 244000228451 Stevia rebaudiana Species 0.000 abstract 1
- 235000006092 Stevia rebaudiana Nutrition 0.000 abstract 1
- 210000004369 blood Anatomy 0.000 description 11
- 239000008280 blood Substances 0.000 description 11
- 230000006870 function Effects 0.000 description 10
- 210000004185 liver Anatomy 0.000 description 10
- 238000012360 testing method Methods 0.000 description 9
- 239000003814 drug Substances 0.000 description 7
- 206010011224 Cough Diseases 0.000 description 6
- 208000002173 dizziness Diseases 0.000 description 6
- 230000004438 eyesight Effects 0.000 description 6
- 230000001737 promoting effect Effects 0.000 description 5
- 206010010774 Constipation Diseases 0.000 description 4
- 206010019233 Headaches Diseases 0.000 description 4
- 208000002193 Pain Diseases 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 235000009508 confectionery Nutrition 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 231100000869 headache Toxicity 0.000 description 4
- 210000003205 muscle Anatomy 0.000 description 4
- 206010010144 Completed suicide Diseases 0.000 description 3
- 230000017531 blood circulation Effects 0.000 description 3
- 210000001124 body fluid Anatomy 0.000 description 3
- 239000010839 body fluid Substances 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 230000036039 immunity Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000005855 radiation Effects 0.000 description 3
- 238000005728 strengthening Methods 0.000 description 3
- 206010051625 Conjunctival hyperaemia Diseases 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 208000012886 Vertigo Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- 208000027418 Wounds and injury Diseases 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 230000007674 genetic toxicity Effects 0.000 description 2
- 231100000025 genetic toxicology Toxicity 0.000 description 2
- 235000013402 health food Nutrition 0.000 description 2
- 230000023597 hemostasis Effects 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 230000027939 micturition Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 231100000889 vertigo Toxicity 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 208000002381 Brain Hypoxia Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 206010007247 Carbuncle Diseases 0.000 description 1
- 208000002177 Cataract Diseases 0.000 description 1
- 206010010726 Conjunctival oedema Diseases 0.000 description 1
- 206010010741 Conjunctivitis Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000721047 Danaus plexippus Species 0.000 description 1
- 206010011878 Deafness Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 208000015220 Febrile disease Diseases 0.000 description 1
- 206010017553 Furuncle Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000008899 Habitual abortion Diseases 0.000 description 1
- 208000031361 Hiccup Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 208000019255 Menstrual disease Diseases 0.000 description 1
- 240000002624 Mespilus germanica Species 0.000 description 1
- 235000017784 Mespilus germanica Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 235000000560 Mimusops elengi Nutrition 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010033557 Palpitations Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- 208000001431 Psychomotor Agitation Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010038743 Restlessness Diseases 0.000 description 1
- 208000025747 Rheumatic disease Diseases 0.000 description 1
- 208000005392 Spasm Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 208000009205 Tinnitus Diseases 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010064996 Ulcerative keratitis Diseases 0.000 description 1
- 235000007837 Vangueria infausta Nutrition 0.000 description 1
- 206010047531 Visual acuity reduced Diseases 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 230000002350 accommodative effect Effects 0.000 description 1
- 201000004484 acute conjunctivitis Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 231100000460 acute oral toxicity Toxicity 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 230000036528 appetite Effects 0.000 description 1
- 235000019789 appetite Nutrition 0.000 description 1
- 206010003549 asthenia Diseases 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 239000010949 copper Substances 0.000 description 1
- 201000007717 corneal ulcer Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000035619 diuresis Effects 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 230000005670 electromagnetic radiation Effects 0.000 description 1
- 230000007368 endocrine function Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 208000027993 eye symptom Diseases 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 210000003608 fece Anatomy 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 210000000232 gallbladder Anatomy 0.000 description 1
- 230000002607 hemopoietic effect Effects 0.000 description 1
- 208000023513 hiccough Diseases 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 210000003127 knee Anatomy 0.000 description 1
- 210000000629 knee joint Anatomy 0.000 description 1
- 210000002414 leg Anatomy 0.000 description 1
- 239000009472 lonicerae flos Substances 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 231100000682 maximum tolerated dose Toxicity 0.000 description 1
- 239000012567 medical material Substances 0.000 description 1
- 230000005906 menstruation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 230000003505 mutagenic effect Effects 0.000 description 1
- 230000004379 myopia Effects 0.000 description 1
- 208000001491 myopia Diseases 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000004310 photopic vision Effects 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 208000008128 pulmonary tuberculosis Diseases 0.000 description 1
- 230000004223 radioprotective effect Effects 0.000 description 1
- 230000000552 rheumatic effect Effects 0.000 description 1
- 230000035943 smell Effects 0.000 description 1
- 230000002048 spasmolytic effect Effects 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 230000005985 stomach dysfunction Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 231100000886 tinnitus Toxicity 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 231100000820 toxicity test Toxicity 0.000 description 1
- 238000009602 toxicology test Methods 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
- 230000009978 visual deterioration Effects 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 208000005494 xerophthalmia Diseases 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
本发明公开了一种具有缓解视疲劳功效的中草药保健口服液,该产品原料配方为1000份保健口服液的中草药原料组成为人参5~10份、菟丝子10~15份、红景天8~12份、何首乌10~15份、刺五加15~20份、桑椹10~13份、生地8~12份、麦冬10~15份、枸杞10~16份、淫羊藿10~18份、决明子15~20份、菊花10~15份、金银花12~18份、鱼腥草10~15份、当归8~12份、水飞蓟5~10份、桑叶5~10份、女贞子10~15份、白术10~15份、甜叶菊10~15份,采用“超声波辅助浸提+蒸馏挥发油+水煎+醇提”工艺制备。该产品具有缓解视疲劳功效好、安全无副作用、饮用方便等优势。
Description
技术领域
本发明涉及一种具有缓解视疲劳功效的中草药保健口服液,特别是一种以植物中草药为原料制成的保健口服液,属中草药保健领域。
背景技术
视疲劳又称眼疲劳,原用以描述与用眼过度相关的一系列症状的名词。因其产生原因复杂多样,多数学者认为视疲劳的产生是眼或全身器质性因素与精神心理因素相互交织形成的结果,属于身心医学范畴,但通常以患者自觉眼部症状为突出表现,因此,在临床上又常称为眼疲劳综合征。根据临床调查,屈光未得到正确矫正和调节过度及光源亮度不充分、环境亮度不均匀等是产生视疲劳的主要原因。当视疲劳严重情况下会产生头痛、眩晕、诱发胃功能障碍、眼肌痉挛、全身不舒服等症状,尤其是随着电脑等视频终端的大量普及,使视疲劳的发生率呈逐渐上升的趋势。因此,视疲劳的形成原因、发病机制和防治越来越得到人们的关注。
中草药是我国传统文化的瑰宝,随着人民生活的逐步提高,人们的保健意识逐渐增强,在缓解视疲劳、预防近视等方面的需求日益增加,中草药在该领域保健食品开发过程中占据着先天优势条件。为传承源远流长的中草药文化,满足人民群众对保健的需求,本发明选取具有补气补益、扶正固本等功效的中草药,研制开发具有缓解视疲劳功效的中草药保健口服液。
发明内容
为克服现有缓解视疲劳产品技术的不足,本发明的目的在于提供一种具有缓解视疲劳、预防视觉危害保健功效的中草药保健口服液害。
本发明上述目的是通过以下技术方案予以实现的:
本发明提供一种具有缓解视疲劳功效的中草药保健口服液,其特征在于: 1000份口服液中中药原料及质量配比为:人参5~10份、菟丝子10~15份、红景天8~12份、何首乌10~15份、刺五加15~20份、桑椹10~13份、生地8~12份、麦冬10~15份、枸杞10~16份、淫羊藿10~18份、决明子15~20份、菊花10~15份、金银花12~18份、鱼腥草10~15份、当归8~12份、水飞蓟5~10份、桑叶5~10份、女贞子10~15份、白术10~15份、甜叶菊10~15份。
本发明的优选技术方案是:一种具有缓解视疲劳功效的中草药保健口服液,其特征在于:其中药原料及质量配比为:人参8份、菟丝子13份、红景天12份、何首乌12份、刺五加16份、桑椹12份、生地10份、麦冬14份、枸杞15份、淫羊藿15份、决明子18份、菊花12份、金银花15份、鱼腥草12份、当归10份、水飞蓟7份、桑叶8份、女贞子13份、白术12份、甜叶菊13份。
本发明提供一种具有缓解视疲劳功效的中草药保健口服液,其特征在于通过以下步骤制备:
(1)分拣称量:将所用中草药分拣,去除杂质等,按照上述比例称重;
(2)原料预处理:根据原料特性不同分别进行原料预处理:
①将人参、菟丝子、红景天、何首乌、刺五加、生地、麦冬、淫羊藿、决明子、菊花、金银花、鱼腥草、当归、水飞蓟、桑叶、女贞子、白术、甜叶菊混合后进行粉碎处理,过40目筛;
②将桑椹、枸杞混合,加入2~3倍纯净水,打浆,然后加入1~2%果胶酶,在40~50℃条件下酶解10~20min;
(3)超声波辅助酶解:原料混合后加入原料质量比3~5倍纯净水,然后加入原料质量比2~3%纤维素酶、1~2%非淀粉多糖酶,在超声波辅助条件下酶解30~60min,酶解温度控制在40~50℃;
(4)离心:离心分离浸提液和中药草残渣;
(5)蒸馏:向中草药残渣中加入3~5倍量的纯净水,收集挥发油8~10h,挥发油单独收集放置,水溶液过滤,与浸提液合并;
(6)挥发油乳化:将收集的挥发油中加入1.5~2.0%的助溶剂吐温-80,加热乳化;
(7)水煎:将蒸馏后的中草药残渣中加入2~3倍量的水,煎煮3次,每次1.5~2h,水煎液与浸提液合并;
(8)减压浓缩:将合并后的水溶液浓缩至1g/ml的清膏,放冷;
(9)醇沉:向清膏中加入95%的乙醇使含醇量达到60~70%,4℃条件下放置48h以上
(10)醇提:向水煎后的中草药残渣中加入4~6倍量的50%乙醇,加热提取2次,提取时间1~1.5h;
(11)合并抽滤:将醇沉后的液体与醇提液合并抽滤;
(12)减压回收:将抽滤液进行减压回收乙醇至无醇味;
(13)混合:趁热向浓缩液中加入乳化好的挥发油,搅拌均匀;
(14)添加辅料:加入0.10~0.15%的山梨酸钾和1~2%的甜味剂,加水搅拌定容;
(15)静置:将口服液半成品常温下静置48h以上;
(16)离心:将口服液半成品3000r/min离心5~10min;
(17)定容分装:将离心后的口服液定容、分装即得口服液成品。
上述甜味剂选用的是木糖醇、低聚异麦芽糖、蜂蜜中的一种或几种的混合物。
本发明中药物组合是在传统中医理论和实践指导下精选药方。本发明中药组合物中:人参有“补五脏、安精神、定魂魄、止惊悸、除邪气、明日开心益智”的功效,“久服轻身延年”,几千年来中草药中人参都被列为上品;菟丝子气味辛,甘,平无毒,主治补肾益精,养肝明目,适用于肝肾不足的腰膝筋骨酸痛,腿脚软弱无力、阳痿遗精、呓语、小便频数、尿有余沥、头晕眼花、视物不清、耳鸣耳聋以及妇女带下、***肝明目、消咳止痛的功效,用于治疗头痛眩晕、目赤肿痛、风热感冒、咳嗽等病症效果显著,还具有提神醒脑的功效;金银花金银花含有多种人体必须的微量元素和化学成分,同时含有多种对人体有利的活性酶物质,具有抗衰老,防癌变,轻身健体的良好功效;鱼腥草具有缓解视疲劳作用和增强机体免疫功能的作用,且无任何毒副作用,适用于经常接近辐射源的人员,如X光机和电脑操作人员,以及常看电视的人群;电脑一族必吃的防辐射食物;当归具有补血活血,调经止痛,润肠通便等功效,用于血虚萎黄、眩晕心悸、***、经闭痛经、虚寒腹痛、肠燥便秘、风湿痹痛、跌扑损伤、痈疽疮疡;水飞蓟具有清热解毒,保肝、利胆,保脑,抗X射线等功效;桑叶具有降血压、血脂、抗炎等作用,主要功能为疏散风热,清肺润燥,清肝明目,用于风热感冒,肺热燥咳,头晕头痛,目赤昏花;女贞子性甘、苦,凉,功能主治滋补肝肾,明目乌发,用于眩晕耳鸣,腰膝酸软,须发早白,目暗不明;白术具有健脾益气、燥湿利水、止汗、安胎等功效,用于脾虚食少、腹胀泄泻、痰饮眩悸、水肿、自汗、胎动不安。
本发明精选中草药配方,其药物组分经辨证配伍,在作用上相互佐助,可以预防因用眼过度导致的视疲劳;可以预防由于过高的电磁辐射对视觉***造成影响,可以预防电磁辐射导致的视力下降、干眼症、白内障等。
本发明提供一种具有缓解视疲劳功效的中草药保健口服液,其优势在于:一是科学配伍多种中草药,能有效缓解视疲劳;二是在口服液的制备过程中采用“超声波辅助浸提+蒸馏挥发油+水煎+醇提”的工艺,充分糅合中草药中的缓解视疲劳的功能活性成分,提高治疗效果;三是口服液安全无副作用,饮用方便。
本发明提供一种缓解视疲劳的中草药保健口服液,通过动物试验进行保健口服液的毒理学试验及安全性评价。小鼠急性经口毒性试验结果表明,本保健口服液对小鼠急性经口最大耐受剂量大于高剂量组75mg/kg·bw; 遗传毒性试验小鼠骨髓细胞微核试验和小鼠***畸形试验两项试验结果均为阴性,表明该保健口服液无致突变作用;由大鼠30d喂养试验可知,大鼠体征行为正常、体态健康、血液及血液生化指标也无异常变化,因此75mg/kg·bw的剂量(人体推荐量的150倍)属于安全剂量;遗传毒性试验和大鼠30d喂养试验结果均为阴性,因此确定本保健饮料属无毒类食品,人可以安全放心食用。
具体实施方式
下面结合实施例对本发明做进一步说明。
实施例1:
一种具有缓解视疲劳功效的中草药保健口服液,通过以下步骤制备:
(1)分拣称量:将所用中草药分拣,去除杂质等,按照每1000份口服液中人参8份、菟丝子13份、红景天12份、何首乌12份、刺五加16份、桑椹12份、生地10份、麦冬14份、枸杞15份、淫羊藿15份、决明子18份、菊花12份、金银花15份、鱼腥草12份、当归10份、水飞蓟7份、桑叶8份、女贞子13份、白术12份、甜叶菊13份比例称重;
(2)原料预处理:根据原料特性不同分别进行原料预处理:
①将人参、菟丝子、红景天、何首乌、刺五加、生地、麦冬、淫羊藿、决明子、菊花、金银花、鱼腥草、当归、水飞蓟、桑叶、女贞子、白术、甜叶菊混合后进行粉碎处理,过40目筛;
②将桑椹、枸杞混合,加入2.5倍纯净水,打浆,然后加入1.5%果胶酶,在40~50℃条件下酶解15min;
(3)超声波辅助酶解:原料混合后加入原料质量比4倍纯净水,然后加入原料质量比2.5%纤维素酶、1.5%非淀粉多糖酶,在超声波辅助条件下酶解45min,酶解温度控制在40~50℃;
(4)离心:离心分离浸提液和中药草残渣;
(5)蒸馏:向中草药残渣中加入4倍量的纯净水,收集挥发油9h,挥发油单独收集放置,水溶液过滤,与浸提液合并;
(6)挥发油乳化:将收集的挥发油中加入1.8%的助溶剂吐温-80,加热乳化;
(7)水煎:将蒸馏后的中草药残渣中加入2.5倍量的水,煎煮3次,每次1.8h,水煎液与浸提液合并;
(8)减压浓缩:将合并后的水溶液浓缩至1g/ml的清膏,放冷;
(9)醇沉:向清膏中加入95%的乙醇使含醇量达到60~70%,4℃条件下放置48h以上
(10)醇提:向水煎后的中草药残渣中加入5倍量的50%乙醇,加热提取2次,提取时间1.2h;
(11)合并抽滤:将醇沉后的液体与醇提液合并抽滤;
(12)减压回收:将抽滤液进行减压回收乙醇至无醇味;
(13)混合:趁热向浓缩液中加入乳化好的挥发油,搅拌均匀;
(14)添加辅料:加入0.12%的山梨酸钾和1.5%的木糖醇,加水搅拌定容;
(15)静置:将口服液半成品常温下静置48h以上;
(16)离心:将口服液半成品3000r/min离心8min;
(17)定容分装:将离心后的口服液定容、分装即得口服液成品。
实施例2:
一种具有缓解视疲劳功效的中草药保健口服液,通过以下步骤制备:
(1)分拣称量:将所用中草药分拣,去除杂质等,按照每1000份口服液中人参10份、菟丝子10份、红景天12份、何首乌10份、刺五加20份、桑椹10份、生地12份、麦冬10份、枸杞16份、淫羊藿10份、决明子20份、菊花10份、金银花18份、鱼腥草10份、当归12份、水飞蓟5份、桑叶10份、女贞子10份、白术15份、甜叶菊10份比例称重;
(2)原料预处理:根据原料特性不同分别进行原料预处理:
①将人参、菟丝子、红景天、何首乌、刺五加、生地、麦冬、淫羊藿、决明子、菊花、金银花、鱼腥草、当归、水飞蓟、桑叶、女贞子、白术、甜叶菊混合后进行粉碎处理,过40目筛;
②将桑椹、枸杞混合,加入3倍纯净水,打浆,然后加入2%果胶酶,在40~50℃条件下酶解10min;
(3)超声波辅助酶解:原料混合后加入原料质量比5倍纯净水,然后加入原料质量比3%纤维素酶、2%非淀粉多糖酶,在超声波辅助条件下酶解30min,酶解温度控制在40~50℃;
(4)离心:离心分离浸提液和中药草残渣;
(5)蒸馏:向中草药残渣中加入5倍量的纯净水,收集挥发油8h,挥发油单独收集放置,水溶液过滤,与浸提液合并;
(6)挥发油乳化:将收集的挥发油中加入2.0%的助溶剂吐温-80,加热乳化;
(7)水煎:将蒸馏后的中草药残渣中加入3倍量的水,煎煮3次,每次1.5h,水煎液与浸提液合并;
(8)减压浓缩:将合并后的水溶液浓缩至1g/ml的清膏,放冷;
(9)醇沉:向清膏中加入95%的乙醇使含醇量达到60~70%,4℃条件下放置48h以上
(10)醇提:向水煎后的中草药残渣中加入6倍量的50%乙醇,加热提取2次,提取时间1h;
(11)合并抽滤:将醇沉后的液体与醇提液合并抽滤;
(12)减压回收:将抽滤液进行减压回收乙醇至无醇味;
(13)混合:趁热向浓缩液中加入乳化好的挥发油,搅拌均匀;
(14)添加辅料:加入0.15%的山梨酸钾和2%的低聚异麦芽糖,加水搅拌定容;
(15)静置:将口服液半成品常温下静置48h以上;
(16)离心:将口服液半成品3000r/min离心10min;
(17)定容分装:将离心后的口服液定容、分装即得口服液成品。
实施例3:
一种具有缓解视疲劳功效的中草药保健口服液,通过以下步骤制备:
(1)分拣称量:将所用中草药分拣,去除杂质等,按照每1000份口服液中人参5份、菟丝子15份、红景天8份、何首乌15份、刺五加15份、桑椹13份、生地8份、麦冬15份、枸杞10份、淫羊藿18份、决明子15份、菊花15份、金银花12份、鱼腥草15份、当归8份、水飞蓟10份、桑叶5份、女贞子15份、白术10份、甜叶菊15份比例称重;
(2)原料预处理:根据原料特性不同分别进行原料预处理:
①将人参、菟丝子、红景天、何首乌、刺五加、生地、麦冬、淫羊藿、决明子、菊花、金银花、鱼腥草、当归、水飞蓟、桑叶、女贞子、白术、甜叶菊混合后进行粉碎处理,过40目筛;
②将桑椹、枸杞混合,加入2倍纯净水,打浆,然后加入1%果胶酶,在40~50℃条件下酶解20min;
(3)超声波辅助酶解:原料混合后加入原料质量比3倍纯净水,然后加入原料质量比2%纤维素酶、1%非淀粉多糖酶,在超声波辅助条件下酶解60min,酶解温度控制在40~50℃;
(4)离心:离心分离浸提液和中药草残渣;
(5)蒸馏:向中草药残渣中加入3倍量的纯净水,收集挥发油10h,挥发油单独收集放置,水溶液过滤,与浸提液合并;
(6)挥发油乳化:将收集的挥发油中加入1.5%的助溶剂吐温-80,加热乳化;
(7)水煎:将蒸馏后的中草药残渣中加入2倍量的水,煎煮3次,每次2h,水煎液与浸提液合并;
(8)减压浓缩:将合并后的水溶液浓缩至1g/ml的清膏,放冷;
(9)醇沉:向清膏中加入95%的乙醇使含醇量达到60~70%,4℃条件下放置48h以上
(10)醇提:向水煎后的中草药残渣中加入4倍量的50%乙醇,加热提取2次,提取时间1.5h;
(11)合并抽滤:将醇沉后的液体与醇提液合并抽滤;
(12)减压回收:将抽滤液进行减压回收乙醇至无醇味;
(13)混合:趁热向浓缩液中加入乳化好的挥发油,搅拌均匀;
(14)添加辅料:加入0.10%的山梨酸钾和1%的蜂蜜,加水搅拌定容;
(15)静置:将口服液半成品常温下静置48h以上;
(16)离心:将口服液半成品3000r/min离心5~10min;
(17)定容分装:将离心后的口服液定容、分装即得口服液成品。
本发明提供一种缓解视疲劳的中草药保健口服液,不同的中草药性味各异,功效存在着巨大的差异,不同的中草药组合后存在复杂的相互作用关系,且中草药之间的配比比较密切,不同配比也将使君臣佐使关系发生实质性的变化,从而使复合中草药的关系发生实质性改变。本申请通过人参、菟丝子、红景天、何首乌、刺五加、桑椹、生地、麦冬、枸杞、淫羊藿、决明子、菊花、金银花、鱼腥草、当归、水飞蓟、桑叶、女贞子、白术、甜叶菊等中草药彼此间存在复杂的相互作用关系,合理配比,取得了预料不到的技术效果,使缓解视疲劳中草药保健口服液的关系发生实质性改变,本申请中草药保健口服液的总抗氧化能力达到485.36±23.47U/mL,改变中草药配比或中草药组成会降低保健口服液的抗氧化能力。根据《保健食品功能学评价程序和检验方法》对本申请产品进行了功能性评价,结果表明试验组小鼠骨骼细胞微核率显著降低,外周细胞数和骨髓细胞DNA含量明显增加,与对照组相比差异显著,证明了本发明产品对辐射危害具有一定的保护作用;用自身及组间对照的方法对产品的缓解视疲劳功效进行评价,随机将50名视疲劳者分为试验组和对照组,连续服用30h后,试验组视疲劳感明显减轻,明视持久度平均提高24.17%以上,总有效率94%以上,实验前后血、尿、便常规检查及血生化检验指标均正常,证明了本发明产品具有较好的缓解视疲劳的功效。
以上实施例仅用于说明本发明的技术方案,而非对其进行限制;尽管参照前述实施例对被发明进行了详细的说明,但对于本领域的普通技术人员来说,依然可以对前述实施例所记载的技术方案进行修改,或者对其中部分技术特征进行等同替换;而对这些修改或者替换,并不使相应技术方案的本质脱离本发明所要求保护的技术方案的精神和范围。
Claims (2)
1.一种具有缓解视疲劳功效的中草药保健口服液,其特征在于制备工艺包括以下步骤:
(1)分拣称量:将所用中草药分拣,去除杂质等,按照每1000份口服液中人参5~10份、菟丝子10~15份、红景天8~12份、何首乌10~15份、刺五加15~20份、桑椹10~13份、生地8~12份、麦冬10~15份、枸杞10~16份、淫羊藿10~18份、决明子15~20份、菊花10~15份、金银花12~18份、鱼腥草10~15份、当归8~12份、水飞蓟5~10份、桑叶5~10份、女贞子10~15份、白术10~15份、甜叶菊10~15份比例称重;
(2)原料预处理:根据原料特性不同分别进行原料预处理:
①将人参、菟丝子、红景天、何首乌、刺五加、生地、麦冬、淫羊藿、决明子、菊花、金银花、鱼腥草、当归、水飞蓟、桑叶、女贞子、白术、甜叶菊混合后进行粉碎处理,过40目筛;
②将桑椹、枸杞混合,加入2~3倍纯净水,打浆,然后加入1~2%果胶酶,在40~50℃条件下酶解10~20min;
(3)超声波辅助酶解:原料混合后加入原料质量比3~5倍纯净水,然后加入原料质量比2~3%纤维素酶、1~2%非淀粉多糖酶,在超声波辅助条件下酶解30~60min,酶解温度控制在40~50℃;
(4)离心:离心分离浸提液和中药草残渣;
(5)蒸馏:向中草药残渣中加入3~5倍量的纯净水,收集挥发油8~10h,挥发油单独收集放置,水溶液过滤,与浸提液合并;
(6)挥发油乳化:将收集的挥发油中加入1.5~2.0%的助溶剂吐温-80,加热乳化;
(7)水煎:将蒸馏后的中草药残渣中加入2~3倍量的水,煎煮3次,每次1.5~2h,水煎液与浸提液合并;
(8)减压浓缩:将合并后的水溶液浓缩至1g/ml的清膏,放冷;
(9)醇沉:向清膏中加入95%的乙醇使含醇量达到60~70%,4℃条件下放置48h以上
(10)醇提:向水煎后的中草药残渣中加入4~6倍量的50%乙醇,加热提取2次,提取时间1~1.5h;
(11)合并抽滤:将醇沉后的液体与醇提液合并抽滤;
(12)减压回收:将抽滤液进行减压回收乙醇至无醇味;
(13)混合:趁热向浓缩液中加入乳化好的挥发油,搅拌均匀;
(14)添加辅料:加入0.10~0.15%的山梨酸钾和1~2%的甜味剂,加水搅拌定容;
(15)静置:将口服液半成品常温下静置48h以上;
(16)离心:将口服液半成品3000r/min离心5~10min;
(17)定容分装:将离心后的口服液定容、分装即得口服液成品。
2.根据权利要求1所述一种具有缓解视疲劳功效的中草药保健口服液,其特征在于所述甜味剂选用的是木糖醇、低聚异麦芽糖、蜂蜜中的一种或几种的混合物。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510054127.6A CN104547534B (zh) | 2015-02-03 | 2015-02-03 | 一种具有缓解视疲劳功效的中草药保健口服液 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201510054127.6A CN104547534B (zh) | 2015-02-03 | 2015-02-03 | 一种具有缓解视疲劳功效的中草药保健口服液 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN104547534A true CN104547534A (zh) | 2015-04-29 |
CN104547534B CN104547534B (zh) | 2018-08-24 |
Family
ID=53065305
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201510054127.6A Expired - Fee Related CN104547534B (zh) | 2015-02-03 | 2015-02-03 | 一种具有缓解视疲劳功效的中草药保健口服液 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN104547534B (zh) |
Cited By (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104888046A (zh) * | 2015-07-07 | 2015-09-09 | 青岛嘉瑞生物技术有限公司 | 一种具有改善贫血功效的中草药保健口服液 |
CN104921132A (zh) * | 2015-07-08 | 2015-09-23 | 青岛嘉瑞生物技术有限公司 | 一种具有润肺止咳消喘功效的中草药保健口服液 |
CN104921131A (zh) * | 2015-07-08 | 2015-09-23 | 青岛嘉瑞生物技术有限公司 | 一种具有治疗便秘功效的营养强化粉 |
CN104920740A (zh) * | 2015-07-20 | 2015-09-23 | 青海省通天河藏药制药有限责任公司 | 一种改善视力代用茶 |
CN104938918A (zh) * | 2015-07-06 | 2015-09-30 | 青岛嘉瑞生物技术有限公司 | 一种具有调节血脂功效的营养面粉 |
CN105055707A (zh) * | 2015-07-22 | 2015-11-18 | 青岛浩大海洋保健食品有限公司 | 一种降血脂鲨鱼软骨粉中草药保健口服液及制备方法 |
CN105055569A (zh) * | 2015-07-22 | 2015-11-18 | 青岛浩大海洋保健食品有限公司 | 一种抗肿瘤提高免疫力鲨鱼翅骨粉中草药保健口服液及制备方法 |
CN105055648A (zh) * | 2015-07-22 | 2015-11-18 | 青岛浩大海洋保健食品有限公司 | 一种抗衰老鲨鱼软骨粉中草药保健口服液及制备方法 |
CN105919132A (zh) * | 2016-05-19 | 2016-09-07 | 河南洛阳红牡丹产业研发有限公司 | 一种牡丹多叶露的制备方法 |
CN106753961A (zh) * | 2016-12-22 | 2017-05-31 | 广州聚注专利研发有限公司 | 一种改善视疲劳的女性保健酒 |
CN107362285A (zh) * | 2017-09-07 | 2017-11-21 | 西安雅顿生物科技有限公司 | 一种抗辐射润眼液制备方法 |
CN108175087A (zh) * | 2017-12-25 | 2018-06-19 | 广州美耕食品有限公司 | 一种姜黄水飞蓟荞麦花粉片 |
CN110157589A (zh) * | 2019-06-04 | 2019-08-23 | 阳信鼎致集团有限公司 | 一种鸭梨保健醋及其制备工艺 |
CN111012840A (zh) * | 2019-12-26 | 2020-04-17 | 刘永 | 一种缓解眼部疲劳的人参菊花养生茶及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1262072A (zh) * | 1999-01-30 | 2000-08-09 | 李连成 | 元气平衡饮料 |
JP2005287376A (ja) * | 2004-03-31 | 2005-10-20 | Q P Corp | 眼精疲労用飲食品組成物 |
CN1843457A (zh) * | 2006-02-20 | 2006-10-11 | 王信锁 | 一种提高视力保护眼睛的口服液 |
CN104116900A (zh) * | 2014-08-07 | 2014-10-29 | 赵西迷 | 一种防治近视的中药敷贴及其制备方法 |
-
2015
- 2015-02-03 CN CN201510054127.6A patent/CN104547534B/zh not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1262072A (zh) * | 1999-01-30 | 2000-08-09 | 李连成 | 元气平衡饮料 |
JP2005287376A (ja) * | 2004-03-31 | 2005-10-20 | Q P Corp | 眼精疲労用飲食品組成物 |
CN1843457A (zh) * | 2006-02-20 | 2006-10-11 | 王信锁 | 一种提高视力保护眼睛的口服液 |
CN104116900A (zh) * | 2014-08-07 | 2014-10-29 | 赵西迷 | 一种防治近视的中药敷贴及其制备方法 |
Non-Patent Citations (4)
Title |
---|
上海中医学院: "《中草药学》", 30 April 1974 * |
易阳等: "龙眼多糖超声波-酶解辅助提取工艺优化", 《农业机械学报》 * |
朱炜敏: "《常见眼部疾病的中医预防和护养》", 31 October 2013 * |
许利平: "《实用中成药手册》", 31 October 2010 * |
Cited By (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN104938918A (zh) * | 2015-07-06 | 2015-09-30 | 青岛嘉瑞生物技术有限公司 | 一种具有调节血脂功效的营养面粉 |
CN104888046A (zh) * | 2015-07-07 | 2015-09-09 | 青岛嘉瑞生物技术有限公司 | 一种具有改善贫血功效的中草药保健口服液 |
CN104888046B (zh) * | 2015-07-07 | 2018-05-25 | 杜婷 | 一种具有改善贫血功效的中草药保健口服液 |
CN104921132A (zh) * | 2015-07-08 | 2015-09-23 | 青岛嘉瑞生物技术有限公司 | 一种具有润肺止咳消喘功效的中草药保健口服液 |
CN104921131A (zh) * | 2015-07-08 | 2015-09-23 | 青岛嘉瑞生物技术有限公司 | 一种具有治疗便秘功效的营养强化粉 |
CN104920740A (zh) * | 2015-07-20 | 2015-09-23 | 青海省通天河藏药制药有限责任公司 | 一种改善视力代用茶 |
CN105055569A (zh) * | 2015-07-22 | 2015-11-18 | 青岛浩大海洋保健食品有限公司 | 一种抗肿瘤提高免疫力鲨鱼翅骨粉中草药保健口服液及制备方法 |
CN105055648A (zh) * | 2015-07-22 | 2015-11-18 | 青岛浩大海洋保健食品有限公司 | 一种抗衰老鲨鱼软骨粉中草药保健口服液及制备方法 |
CN105055707A (zh) * | 2015-07-22 | 2015-11-18 | 青岛浩大海洋保健食品有限公司 | 一种降血脂鲨鱼软骨粉中草药保健口服液及制备方法 |
CN105919132A (zh) * | 2016-05-19 | 2016-09-07 | 河南洛阳红牡丹产业研发有限公司 | 一种牡丹多叶露的制备方法 |
CN106753961A (zh) * | 2016-12-22 | 2017-05-31 | 广州聚注专利研发有限公司 | 一种改善视疲劳的女性保健酒 |
CN107362285A (zh) * | 2017-09-07 | 2017-11-21 | 西安雅顿生物科技有限公司 | 一种抗辐射润眼液制备方法 |
CN108175087A (zh) * | 2017-12-25 | 2018-06-19 | 广州美耕食品有限公司 | 一种姜黄水飞蓟荞麦花粉片 |
CN110157589A (zh) * | 2019-06-04 | 2019-08-23 | 阳信鼎致集团有限公司 | 一种鸭梨保健醋及其制备工艺 |
CN111012840A (zh) * | 2019-12-26 | 2020-04-17 | 刘永 | 一种缓解眼部疲劳的人参菊花养生茶及其制备方法 |
Also Published As
Publication number | Publication date |
---|---|
CN104547534B (zh) | 2018-08-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN104547534B (zh) | 一种具有缓解视疲劳功效的中草药保健口服液 | |
CN103251867B (zh) | 一种治疗糖尿病的中药复方药物及其制备方法 | |
CN103041209B (zh) | 一种治疗肾阴虚的中药制剂及其制备方法 | |
CN104922299A (zh) | 一种预防和治疗糖尿病性视网膜病变的中草药保健口服液 | |
CN104958445A (zh) | 一种防治风热上攻目赤肿痛的蔓荆子口服液及其制备方法 | |
CN103749819B (zh) | 一种降糖降脂的山茱萸保健茶及其制备方法 | |
CN104256820A (zh) | 一种具有抗辐射功效的中草药保健口服液 | |
CN103083522B (zh) | 一种生发育发的中药组合物、制备方法及应用 | |
CN101757359A (zh) | 一种益肾产品及其制备方法 | |
CN105394282A (zh) | 一种可降压降糖降脂的葛根保健茶 | |
CN104547598A (zh) | 一种治疗神经衰弱的中药制剂及制备方法 | |
CN104258188A (zh) | 一种具有治疗糖尿病功效的保健口服液 | |
CN104524479B (zh) | 一种治疗经前期综合征的中药组合物及其制备方法 | |
CN106350411A (zh) | 一种保健养生酒的制备方法 | |
CN106361976A (zh) | 一种安神助眠养颜复方制剂及其制备方法 | |
CN105343795A (zh) | 一种治疗失眠症的药物及其制备方法 | |
CN105410268A (zh) | 一种明目降脂的菟丝子保健茶及其制备方法 | |
CN112439038A (zh) | 一种快速改善睡眠的药物 | |
CN105062819B (zh) | 补肾壮阳养生酒 | |
CN104606565B (zh) | 预防及治疗眼部疾病的中药胶囊 | |
CN104096073A (zh) | 一种治疗***的中药组合物及其制备方法 | |
CN103100031A (zh) | 治疗肝肾阴虚不寐的中草药 | |
CN103784865A (zh) | 治疗心气不足阴亏肝郁心悸的中草药 | |
CN103495022B (zh) | 一种辅助治疗艾滋病的中药 | |
CN102366619A (zh) | 一种用于治疗气血虚、失眠引起***的药物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
C10 | Entry into substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180717 Address after: 266000 217 Liaoyang West Road, Shibei District, Qingdao, Shandong Applicant after: QINGDAO WOMEN AND CHILDREN'S HOSPITAL Address before: 266034 four Ningxia 601, Ningxia Road, Shinan District, Qingdao, Shandong. Applicant before: Guo Dianqiang |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CF01 | Termination of patent right due to non-payment of annual fee | ||
CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20180824 Termination date: 20190203 |